文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

德拉马尼、利奈唑胺、左氧氟沙星和吡嗪酰胺治疗氟喹诺酮敏感耐多药结核病:II/III期多中心随机开放标签临床试验方案

Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
PubMed 文献 · Trials · 2019-01-16

该研究为II/III期多中心随机开放标签非劣效性试验,比较含德拉马尼、利奈唑胺、左氧氟沙星和吡嗪酰胺的9或12个月短程方案与含注射剂的20-24个月常规方案,治疗氟喹诺酮敏感耐多药结核病。主要结局为治疗开始后24个月的治疗成功率,每组需102人,共204人。

要点

  • 试验评估4种口服药组成的短程方案(9或12个月)治疗氟喹诺酮敏感MDR-TB。
  • 对照组使用含注射剂的常规方案,疗程20-24个月。
  • 主要结局为治疗开始后24个月的治疗成功率,设计为非劣效性。

核心结论

  • 该试验将揭示含德拉马尼、利奈唑胺、左氧氟沙星和吡嗪酰胺的短程口服方案治疗氟喹诺酮敏感MDR-TB的有效性和安全性。

研究设计与样本

  • II/III期、多中心、随机、开放标签、非劣效性临床试验,比较新短程方案与WHO推荐的常规方案。
  • 对照组使用含注射剂的二线药物常规方案,疗程20-24个月。
  • 试验组使用含德拉马尼、利奈唑胺、左氧氟沙星和吡嗪酰胺的方案,疗程9或12个月,取决于痰培养转阴时间。
  • 基于α=0.025(单侧)、80%把握度、两组治疗成功率差异<10%(80% vs. 70%)、试验组预期实际成功率90%,计算每组需48人;假设氟喹诺酮敏感MDR-TB比例为50%、失访率5%,每组需102人,共204人。

关键数值与推荐

  • 主要结局为治疗开始后24个月的治疗成功率。
  • 次要结局包括液体和固体培养基上的痰培养转阴时间、治疗2和6个月后液体培养基痰培养转阴比例、根据吡嗪酰胺耐药的治疗成功率、以及按CTCAE评估的3级及以上不良事件发生率。

临床怎么用

  • 若试验证明非劣效,该短程全口服方案可能为氟喹诺酮敏感MDR-TB提供更短、更便利的治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment success rates of multidrug-resistant tuberculosis (MDR-TB) remain unsatisfactory, and long-term use of second-line anti-TB drugs is accompanied by the frequent occurrence of adverse events, low treatment compliance, and high costs. The development of new efficient regimens with shorter treatment durations for MDR-TB will solve these issues and improve treatment outcomes. METHODS: This study is a phase II/III, multicenter, randomized, open-label clinical trial of non-inferiority design comparing a new regimen to the World Health Organization-endorsed conventional regimen for fluoroquinolone-sensitive MDR-TB. The control arm uses a conventional treatment regimen with second-line drugs including injectables for 20-24 months. The investigational arm uses a new shorter regimen including delamanid, linezolid, levofloxacin, and pyrazinamide for 9 or 12 months depending on time to sputum culture conversion. The primary outcome is the treatment success rate at 24 months after treatment initiation. Secondary outcomes include time to sputum culture conversion on liquid and solid media, proportions of sputum culture conversion on liquid media after 2 and 6 months of treatment, treatment success rate according to pyrazinamide resistance, and occurrence of adverse events grade 3 and above as evaluated by the Common Terminology Criteria for Adverse Events. Based on an α = 0.025 level of significance (one-sided test), a power of 80%, and a < 10% difference in treatment success rate between the control and investigational arms (80% vs. 70%) when the anticipated actual success rate in the treatment group is assumed to be 90%, the number of participants needed per arm to show non-inferiority of the investigational regimen was calculated as 48. Additionally, assuming the proportion of fluoroquinolone-susceptible MDR-TB among participants as 50%, and 5% loss to follow-up, the number of participants is calculated as N/( 0.50 × 0.95), resulting in 102 persons per group (204 in total). DISCUSSION: This trial will reveal the effectiveness and safety of a new shorter regimen comprising four oral drugs, including delamanid, linezolid, levofloxacin, and pyrazinamide, for the treatment of fluoroquinolone-sensitive MDR-TB. Results from this trial will provide evidence for adopting a shorter and more convenient treatment regimen for MDR-TB. TRIAL REGISTRATION: ClincalTrials.gov, NCT02619994 . Registered on 2 December 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lee M, Mok J, Kim DK, et al. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial. Trials. 2019. PMID: 30651149. doi:10.1186/s13063-018-3053-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。